|
🐜
|
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
34 auth.
E. Rozeman,
E. Hoefsmit,
I. Reijers,
R. Saw,
J. Versluis,
O. Krijgsman,
P. Dimitriadis,
K. Sikorska,
B. A. Van de Wiel,
H. Eriksson,
M. González,
A. Torres Acosta,
L. Grijpink-Ongering,
K. Shannon,
J. Haanen,
...
J. Stretch,
S. Ch’ng,
O. Nieweg,
H. Mallo,
S. Adriaansz,
R. Kerkhoven,
S. Cornelissen,
A. Broeks,
W. Klop,
C. Zuur,
W. V. van Houdt,
D. Peeper,
A. Spillane,
A. V. Van Akkooi,
R. Scolyer,
T. Schumacher,
A. Menzies,
G. Long,
C. Blank
|
7 |
2021 |
7
🐜
|
|
🐬
|
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O’Donnell,
E. Hoefsmit,
M. Smyth,
C. Blank,
M. Teng
|
6 |
2019 |
6
🐬
|
|
🐜
|
Eosinophils capture viruses, a capacity that is defective in asthma
14 auth.
Yanaika S. Sabogal Piñeros,
S. Bal,
A. Dijkhuis,
C. Majoor,
B. Dierdorp,
T. Dekker,
E. Hoefsmit,
P. Bonta,
Daisy I. Picavet,
N. N. van der Wel,
...
L. Koenderman,
P. Sterk,
L. Ravanetti,
R. Lutter
|
6 |
2019 |
6
🐜
|
|
🐜
|
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy.
23 auth.
S. Iyer,
Shuang Zhang,
S. Yucel,
H. Horn,
Sean G Smith,
Ferenc Reinhardt,
E. Hoefsmit,
Bimarzhan Assatova,
J. Casado,
Marie-Charlotte Meinsohn,
...
M Inmaculada Barrasa,
George W. Bell,
Fernando Pérez-Villatoro,
K. Huhtinen,
J. Hynninen,
J. Oikkonen,
Pamoda Galhenage,
S. Pathania,
Paula T Hammond,
Ben Neel,
A. Färkkilä,
D. Pépin,
Robert A. Weinberg
|
6 |
2020 |
6
🐜
|
|
🦁
|
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
21 auth.
E. Hoefsmit,
E. Rozeman,
Trieu-My Van,
P. Dimitriadis,
O. Krijgsman,
J. Conway,
I. Pires da Silva,
J. E. van der Wal,
S. Ketelaars,
Kaspar Bresser,
...
A. Broeks,
R. Kerkhoven,
J. Reeves,
S. Warren,
P. Kvistborg,
R. Scolyer,
E. Kapiteijn,
D. Peeper,
G. Long,
T. Schumacher,
C. Blank
|
5 |
2020 |
5
🦁
|
|
🐜
|
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
17 auth.
Zhengkui Zhang,
Xiangjun Kong,
M. Ligtenberg,
Susan E. van Hal-van Veen,
Nils L. Visser,
Beaunelle de Bruijn,
Kelly E. Stecker,
Pim W. van der Helm,
T. Kuilman,
E. Hoefsmit,
...
David W. Vredevoogd,
Georgi Apriamashvili,
Beau Baars,
E. Voest,
S. Klarenbeek,
M. Altelaar,
D. Peeper
|
4 |
2022 |
4
🐜
|
|
🦁
|
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
E. Hoefsmit,
E. Rozeman,
J. Haanen,
C. Blank
|
4 |
2019 |
4
🦁
|
|
🐜
|
Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.
20 auth.
E. Rozeman,
I. Reijers,
E. Hoefsmit,
K. Sikorska,
O. Krijgsman,
B. Wiel,
P. Dimitriadis,
H. Eriksson,
Maria Gonzalez,
L. Grijpink-Ongering,
...
R. Kerkhoven,
A. Broeks,
W. Klop,
A. Spillane,
R. Saw,
A. V. Akkooi,
R. Scolyer,
A. Menzies,
G. Long,
C. Blank
|
4 |
2020 |
4
🐜
|
|
🐜
|
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
20 auth.
E. A. Rozeman,
A. Menzies,
O. Krijgsman,
E. Hoefsmit,
B. Wiel,
K. Sikorska,
Trieu-My Van,
H. Eriksson,
C. Bierman,
Maria Gonzalez,
...
K. Shannon,
A. Broeks,
R. Kerkhoven,
A. Spillane,
R. Saw,
A. V. Akkooi,
R. Scolyer,
J. Hansson,
G. Long,
C. Blank
|
4 |
2019 |
4
🐜
|
